# Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France

> **NCT02714855** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 2081 (actual)

## Conditions studied

- Anticoagulation

## Interventions

- **DRUG:** Apixaban

## Key facts

- **NCT ID:** NCT02714855
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 2081 (ACTUAL)
- **Last updated:** 2017-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02714855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02714855, "Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02714855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*